- Curida Holding AS has received a significant growth investment from Signet Healthcare Partners and existing shareholders.
- The company’s COO, Anders Larsson (right) has been appointed as the new Chief Executive Officer, effective from May 1st, 2024.
Curida Holding AS, a Norway-based contract manufacturers, has announced a significant growth investment from Signet Healthcare Partners, a New York-based healthcare private equity firm, along with existing shareholders. This investment, ranging between 230M Nok and 260M Nok, will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position. However, the exact details of the investment have not been officially disclosed.
In conjunction with Signet’s investment, Signet is joining the Board of Directors. Ole J. Dahlberg has been appointed as Chairman of the Board. Dahlberg stated, “We are very pleased to welcome Signet in as a significant shareholder in Curida. Signet brings strong relevant industry experience and a track record of CDMO investing. We are excited by the opportunity to further accelerate growth and improve products for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients.”
On behalf of the board, Dahlberg thanked Per Thoresen, who has been acting Chairman, for his valuable contributions to Curida over the past 9 years. The Board has appointed Anders Larsson, the company’s Chief Operating Officer, as CEO, effective May 1st, 2024.
Larsson comes with extensive experience in management, operations, and strategic development from the pharma industry. His former roles include CEO in Boots Pharmacies/Alliance Healthcare in Norway (Cencora) and he has held multiple management roles in the food & beverage industry with Orkla and Carlsberg. Larsson holds a MSc in Chemical Engineering from Chalmers University and Imperial College and a BSc in finance from Gothenburg University.
 Overview of outsourcing trends 
